, Tracking Stock Market Picks
Enter Symbol:
Alkermes, Inc. (ALKS) [hlAlert]

down 0.22 %

Alkermes, Inc. (ALKS) rated Overweight with price target $74 by Barclays

Posted on: Thursday,  May 21, 2015  12:25 PM ET by Barclays

Barclays rated Overweight Alkermes, Inc. (NASDAQ: ALKS) on 05/21/2015, when the stock price was $61.31. Since
then, Alkermes, Inc. has lost 0.23% as of 01/21/2016's recent price of $61.17.
If you would have followed this Barclays's recommendation on ALKS, you would have lost 0.22% of your investment in 245 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/21/2015 12:25 PM Buy
61.31 74.00
as of 8/27/2015
1 Week down  -8.98 %
1 Month down  -8.68 %
3 Months up  1.95 %
1 YTD down  -0.22 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy